FIRST FINANCIAL CORP /IN/ GSK — GLAXOSMITHKLINE PLC ADR

Ownership history in FIRST FINANCIAL CORP /IN/  ·  57 quarters on record

AI Ownership Summary

FIRST FINANCIAL CORP /IN/ reported GLAXOSMITHKLINE PLC ADR (GSK) in 57 quarterly 13F filings from 2024 Q1 through 2026 Q2. Peak portfolio weight reached 0.01% in 2024 Q1. The latest visible filing shows GSK at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this GSK ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was FIRST FINANCIAL CORP /IN/'s position in GLAXOSMITHKLINE PLC ADR, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q2

GSK was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.01% in 2024 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2026 Q2

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

GSK stock page FIRST FINANCIAL CORP /IN/ fund profile FIRST FINANCIAL CORP /IN/ full holdings
How FIRST FINANCIAL CORP /IN/ held GSK — position size vs. price
% of Fund (quarterly)    GSK price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q2 UNCHANGED — — — 252 — 0% 0.00% $13K 2026-07-07 $53.32
2026 Q1 UNCHANGED — — — 252 — 0% 0.01% $14K 2026-04-07 $55.33
2025 Q4 UNCHANGED — — — 252 — 0% 0.00% $12K 2026-01-13 $49.05
2025 Q3 UNCHANGED — — — 252 — 0% 0.00% $11K 2025-10-09 $42.33
2025 Q2 UNCHANGED — — — 252 — 0% 0.00% $10K 2025-07-09 $37.63
2025 Q1 REDUCED 7.4% +0.3% ❌ 252 -20 -7.4% 0.00% $10K 2025-04-10 $32.02
2024 Q4 UNCHANGED — — — 272 — 0% 0.00% $9K 2025-01-13 $30.82
2024 Q3 UNCHANGED — — — 272 — 0% 0.01% $11K 2024-10-24 $35.17
2024 Q2 UNCHANGED — — — 272 — 0% 0.01% $10K 2024-07-11 $35.91
2024 Q1 REDUCED 6.8% -9.7% ✅ 272 -20 -6.8% 0.01% $12K 2024-04-12 $37.23
47 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding GSK

As of 2026 Q2 — sorted by position size

Gilman Hill Asset Management, LLC 3Y 7Y 0.92% Stablepoint Partners, LLC 0.8% TOWER TRUST & INVESTMENT Co 0.73% BONNESS ENTERPRISES INC 3Y 7Y 0.7% Arlington Partners LLC 3Y 7Y 0.51% First Bank & Trust 3Y 7Y 0.32% Norway Savings Bank 3Y 7Y 0.3% Beacon Financial Strategies CORP 0.3% Ballew Advisors, Inc 3Y 7Y 0.27% CULTIVAR CAPITAL, INC. 0.21%

FAQ About FIRST FINANCIAL CORP /IN/ and GSK

These are the practical questions this page is built to answer before you even open the full history table.

How long has FIRST FINANCIAL CORP /IN/ reported owning GSK?

FIRST FINANCIAL CORP /IN/ reported GSK across 10 quarterly 13F filings, from 2024 Q1 through 2026 Q2.

What was the largest reported GSK position in FIRST FINANCIAL CORP /IN/'s portfolio?

The largest reported portfolio weight for GSK was 0.01% in 2024 Q1.

What is the latest reported GSK position on this page?

The most recent filing on this page is 2026 Q2, when FIRST FINANCIAL CORP /IN/ reported 252 shares, equal to 0.00% of portfolio, with an estimated market value of $13K.

What does the chart on this GSK ownership page compare?

The chart compares FIRST FINANCIAL CORP /IN/'s quarterly GSK portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did FIRST FINANCIAL CORP /IN/ time their GSK position?

Based on 13F filing dates vs. subsequent GSK price moves, FIRST FINANCIAL CORP /IN/ correctly timed 7 out of 16 reported position changes (44%). The annualised alpha on GSK relative to SPY over the holding period was +14.8%.

← Back to FIRST FINANCIAL CORP /IN/ Holdings